The research program of the Bio-Targeted axis includes development of new tools for therapeutic, diagnostic and personalized medicine based on organic chemistry and synthetic biology.
New drugs are synthesized and their biological activity analyzed with the aim of bringing lead compounds up to the preclinical trial stage. The drugs themselves are sourced from plants, particularly Alpine genuses, or designed through mechanistic studies of biological processes.
In parallel, we design new molecular tools to help better understand biological processes (telomere maintenance, angiogenesis, etc.). Biotechnology and synthetic biology are developed through engineered enzymes or bacteria to produce active compounds and glycoconjugated vaccines.